Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTPa-HBV-IPV and Hib vaccines in healthy infants
NCT00879827Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2000
- Primary completion
- May 2001
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
01
Overview
Phase 3, open-label, single-arm trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) and Haemophilus b conjugate vaccine in diphtheria, poliomyelitis, hepatitis B (HBV) and 3 more, sponsored by GSK. Primary endpoints: Anti-pertussis toxoid, anti-filamentous hemagglutinin and anti-pertactin antibody titers, Anti-diphtheria toxoid and anti-tetanus toxoid antibody titers and 3 more. Started Sep 2000; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)Haemophilus b conjugate vaccine
03
Conditions
diphtheriapoliomyelitishepatitis B (HBV)Tetanuspertussis
Beyond the preview
Go deeper on NCT00879827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00879827.